Charles River Laboratories (CRL) stock
NYSE
As of the Nov 5, 2026 close (U.S. Eastern)
Events and reference metrics · 2
- Market cap
- $15B
- As of Nov 5, 2026
- P/E
- 357.74x
- Trailing twelve months
- P/B
- 4.66x
- Latest reported equity
- P/S
- 3.78x
- Trailing twelve months
- ROE
- 1.3%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
- Market cap
- $15B
- As of Nov 5, 2026
- P/E
- 357.74x
- Trailing twelve months
- P/B
- 4.66x
- Latest reported equity
- P/S
- 3.78x
- Trailing twelve months
- ROE
- 1.3%
- Trailing twelve months
- Dividend yield
- Not available
- Latest fiscal-year dividends
Multiples use the price as of Nov 5, 2026 and may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · Nov 5, 2026 · Financial period · Trailing twelve months
P/E and P/S use the latest four quarters where available · P/B uses the latest equity · Computed in-house by ChickenStock
P/E
357.74x
P/B
4.66x
P/S
3.78x
Earnings and dividend metrics▾
Earnings
EPS
$0.88
Earnings per share
BPS
$67.23
Book value per share
ROE
1.3%
Return on equity
- EPS — what one share earned over the last four quarters. This company earned $0.88 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $67.23 of net assets.
- ROE — how much the company earned on shareholder equity over a year: 1.3%.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
SEC filingsJul–Sep 2026(FY2026 Q3)
Revenue decreased 2.2% from the same period a year earlier.
Key reported figures come first. Select one to see the same quarter across three years.
Revenue · same quarter, three years
Year-ago quarter $1.01B-2.2%
$1.01B
Jul–Sep '24
$1.01B
Jul–Sep '25
$983M
Jul–Sep '26
The next earnings date has not been confirmed yet.
ⓘ Notes on these figures▾
- Results for Jul–Sep 2026 are from the 10-Q submitted to SEC EDGAR on Nov 4, 2026.
- Earnings per share increased 523.6% from the same quarter a year earlier.
- Revenue decreased 2.2% from the same quarter a year earlier.
- Operating income increased 51.5% from the same quarter a year earlier.
- Net income increased 516.7% from the same quarter a year earlier.
Filed Nov 4, 2026 · 10-Q · SEC EDGAR · View original
Reported results are from SEC EDGAR filings. Reference information only, not investment advice.
Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- FOSTER JAMES CDirector · Oct 22, 2026Open-market sale24,042 shares · $8.4MAvg. price $35031,596 shares held after
- FOSTER JAMES CDirector · Oct 22, 2026Option exercise24,042 shares · $5.9MAvg. price $244.4155,638 shares held after
- Parisotto Shannon MCEVP, Disc & Safety Assessment · Oct 21, 2026Open-market sale2,156 shares · $743KAvg. price $344.414,807 shares held after
- Parisotto Shannon MCEVP, Disc & Safety Assessment · Oct 21, 2026Option exercise2,156 shares · $527KAvg. price $244.416,963 shares held after
- Parisotto Shannon MCEVP, Disc & Safety Assessment · Oct 5, 2026Open-market sale981 shares · $303KAvg. price $308.444,807 shares held after
- Parisotto Shannon MCEVP, Disc & Safety Assessment · Oct 5, 2026Option exercise981 shares · $204KAvg. price $208.445,788 shares held after
- Coleman GlennEVP & Chief Financial Officer · Sep 30, 2026Open-market purchase10 shares · $3KAvg. price $297.4327,762 shares held after
- FOSTER JAMES CDirector · Aug 25, 2026Open-market sale33,561 shares · $10.1MAvg. price $30031,596 shares held after
- FOSTER JAMES CDirector · Aug 25, 2026Option exercise33,561 shares · $6.7MAvg. price $199.4233
Show 2 price lots
- 21,132 shares × $194.12$4.1M
- 12,429 shares × $208.44$2.6M
- Parisotto Shannon MCEVP, Disc & Safety Assessment · Aug 19, 2026Open-market sale2,039 shares · $600KAvg. price $294.124,807 shares held after
- Parisotto Shannon MCEVP, Disc & Safety Assessment · Aug 19, 2026Option exercise2,039 shares · $396KAvg. price $194.126,846 shares held after
- Girshick BirgitChief Executive Officer · Aug 19, 2026Gift528 shares · $0Avg. price $035,485 shares held after
- Andrews Nancy CDirector · Aug 18, 2026Open-market sale573 shares · $163KAvg. price $285.241,438 shares held after
- Andrews Nancy CDirector · Aug 18, 2026Option exercise573 shares · $94KAvg. price $164.32,011 shares held after
- Girshick BirgitChief Executive Officer · Aug 11, 2026Open-market sale6,500 shares · $1.8MAvg. price $279.936,013 shares held after
- Parisotto Shannon MCEVP, Disc & Safety Assessment · Aug 11, 2026Open-market sale3,714 shares · $1.0MAvg. price $279.664,807 shares held after
- Girshick BirgitChief Executive Officer · Aug 11, 2026Option exercise6,500 shares · $1.2MAvg. price $179.6642,513 shares held after
- Parisotto Shannon MCEVP, Disc & Safety Assessment · Aug 11, 2026Option exercise3,714 shares · $667KAvg. price $179.668,521 shares held after
- FOSTER JAMES CDirector · Aug 10, 2026Open-market sale28,733 shares · $7.9MAvg. price $27531,596 shares held after
- FOSTER JAMES CDirector · Aug 10, 2026Option exercise28,733 shares · $5.2MAvg. price $179.6660,329 shares held after
- LaPlume Joseph WEVP, Corp Strategy & Develop · Aug 10, 2026Gift257 shares · $0Avg. price $031,041 shares held after
- Creamer Victoria LEVP & Chief People Officer · Aug 6, 2026Open-market sale4,179 shares · $1.1MAvg. price $259.1630,051 shares held after
- Knell Michael GunnarSVP, Finance and CAO · Aug 6, 2026Open-market sale6,645 shares · $1.7MAvg. price $260.3837
Show 9 price lots
- 1,274 shares × $259.07$330K
- 1,205 shares × $258.53$312K
- 901 shares × $260.63$235K
- 810 shares × $261.45$212K
- 736 shares × $258.53$190K
- 620 shares × $263.94$164K
- 482 shares × $265.17$128K
- 404 shares × $258.53$104K
- 213 shares × $262.37$56K
- Creamer Victoria LEVP & Chief People Officer · Aug 6, 2026Option exercise4,179 shares · $751KAvg. price $179.6634,230 shares held after
- Knell Michael GunnarSVP, Finance and CAO · Aug 6, 2026Option exercise2,345 shares · $460KAvg. price $196.1233
Show 3 price lots
- 1,205 shares × $194.12$234K
- 736 shares × $208.44$153K
- 404 shares × $179.66$73K
- Parisotto Shannon MCEVP, Disc & Safety Assessment · Aug 5, 2026Open-market sale5,046 shares · $1.3MAvg. price $2634,807 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsRecent filing summaries
Newest first by publication date · may differ from the filing date
- AI summary10-QThe company said revenue for the 3 months ended September 26, 2026 decreased to $982.7 million from $1,004.9 million in the year-earlier period, a 2.2% decline, while operating income rose to $202.6 million, or 20.6% of revenue, from $133.8 million, or 13.3%, a year earlier.Published Nov 4, 2026 · Filed Nov 4, 2026Read the summary →
- AI summary8-KThe company said its revenue for Q3 2026 fell to $982.7 million from $1,004.9 million in Q3 2025, a decrease of 2.2%, while organic revenue rose 4.7%. The company cited the divestiture of May 2026 as the main factor behind the revenue decline.Published Nov 4, 2026 · Filed Nov 4, 2026Read the summary →
- AI summary8-KCharles River Laboratories said shareholders approved the 2026 Long-Term Incentive Plan at its 2026 annual meeting of shareholders held on May 5, 2026. The Board of Directors had previously adopted the plan on March 11, 2026, subject to shareholder approval.Published Sep 30, 2026 · Filed May 11, 2026Read the summary →
- The company said revenue for the 3 months ended September 26, 2026 decreased to $982.7 million from $1,004.9 million in the year-earlier period, a 2.2% decline, while operating income rose to $202.6 million, or 20.6% of revenue, from $133.8 million, or 13.3%, a year earlier.Read the full analysis →
- The company said its revenue for Q3 2026 fell to $982.7 million from $1,004.9 million in Q3 2025, a decrease of 2.2%, while organic revenue rose 4.7%. The company cited the divestiture of May 2026 as the main factor behind the revenue decline.Read the full analysis →
Filings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Charles River Laboratories (CRL) stock information
NYSE
Charles River Laboratories (CRL) is listed on NYSE. Its market capitalization is about $15B. On trailing-twelve-month earnings the P/E ratio is 357.74, and the P/B ratio is 4.66. Return on equity is 1.3%. These figures are computed in-house from official filings and are reference information only.
Charles River Laboratories — frequently asked questions
- What is the P/E ratio of Charles River Laboratories (CRL)?
- On a trailing-twelve-month basis, CRL trades at a P/E ratio of 357.74. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Charles River Laboratories?
- CRL has a market capitalization of about $15B. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.